Epizyme Stock Current Valuation
| EPZMDelisted Stock | USD 1.47 0.00 0.00% |
Valuation analysis of Epizyme helps investors to measure Epizyme's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Epizyme's price fluctuation is very steady at this time. Calculation of the real value of Epizyme is based on 3 months time horizon. Increasing Epizyme's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Epizyme is useful when determining the fair value of the Epizyme stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Epizyme. Since Epizyme is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Epizyme Stock. However, Epizyme's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.47 | Real 1.04 | Hype 1.47 |
The real value of Epizyme Stock, also known as its intrinsic value, is the underlying worth of Epizyme Company, which is reflected in its stock price. It is based on Epizyme's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Epizyme's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Epizyme's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Epizyme helps investors to forecast how Epizyme stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Epizyme more accurately as focusing exclusively on Epizyme's fundamentals will not take into account other important factors: Epizyme Company Current Valuation Analysis
Epizyme's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Epizyme Current Valuation | 334.85 M |
Most of Epizyme's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Epizyme is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Epizyme has a Current Valuation of 334.85 M. This is 97.67% lower than that of the Healthcare sector and 92.79% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 97.99% higher than that of the company.
Epizyme Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Epizyme's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Epizyme could also be used in its relative valuation, which is a method of valuing Epizyme by comparing valuation metrics of similar companies.Epizyme is currently under evaluation in current valuation category among related companies.
Epizyme Fundamentals
| Return On Equity | -352.37 | |||
| Return On Asset | -38.96 | |||
| Operating Margin | (582.15) % | |||
| Current Valuation | 334.85 M | |||
| Shares Outstanding | 103.89 M | |||
| Shares Owned By Insiders | 0.58 % | |||
| Shares Owned By Institutions | 90.32 % | |||
| Number Of Shares Shorted | 5.49 M | |||
| Price To Earning | (7.76) X | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 3.97 X | |||
| Revenue | 38.49 M | |||
| Gross Profit | 18.57 M | |||
| EBITDA | (218.82 M) | |||
| Net Income | (236.35 M) | |||
| Cash And Equivalents | 199.73 M | |||
| Cash Per Share | 1.21 X | |||
| Total Debt | 254.44 M | |||
| Current Ratio | 5.87 X | |||
| Book Value Per Share | 1.46 X | |||
| Cash Flow From Operations | (210.47 M) | |||
| Short Ratio | 0.88 X | |||
| Earnings Per Share | (2.29) X | |||
| Price To Earnings To Growth | (0.03) X | |||
| Number Of Employees | 250 | |||
| Beta | -0.45 | |||
| Market Capitalization | 152.73 M | |||
| Total Asset | 217.9 M | |||
| Retained Earnings | (776.94 M) | |||
| Working Capital | 194.61 M | |||
| Current Asset | 213.06 M | |||
| Current Liabilities | 18.45 M | |||
| Z Score | -7.5 |
About Epizyme Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Epizyme's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Epizyme using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Epizyme based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Epizyme in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Epizyme's short interest history, or implied volatility extrapolated from Epizyme options trading.
Pair Trading with Epizyme
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Epizyme position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Epizyme will appreciate offsetting losses from the drop in the long position's value.Moving against Epizyme Stock
| 0.76 | VRTX | Vertex Pharmaceuticals | PairCorr |
| 0.52 | CSLLY | CSL | PairCorr |
| 0.5 | REGN | Regeneron Pharmaceuticals | PairCorr |
| 0.5 | CMXHF | CSL Limited | PairCorr |
The ability to find closely correlated positions to Epizyme could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Epizyme when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Epizyme - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Epizyme to buy it.
The correlation of Epizyme is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Epizyme moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Epizyme moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Epizyme can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Epizyme information on this page should be used as a complementary analysis to other Epizyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Epizyme Stock
If you are still planning to invest in Epizyme check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Epizyme's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |